[Corrections] Correction to Lancet Oncol 2024; 25: 744–59

Fürstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2024; 25: 744–59—In figure 3 of this Article, the key differentiating between groups with measurable residual disease status of <10−4 or ≥10−4 and the x-axis label were incorrect. These corrections have been made to the online version as of June 24, 2024.